Zentalis Pharmaceuticals coverage initiated with outperform rating and $8 target
ZNTL•Leerink Partners assumed coverage of Zentalis Pharmaceuticals with an outperform rating and an $8 price target, versus its previous market perform rating and $4 target.
Related News
AstraZeneca completes $2 billion equity investment in Summit Therapeutics
SMMT•
AIBotics names Empulser founder Patrick Tsang strategic adviser, eyes CEO appointment after deal closes
AIBT•
C.H. Robinson agrees to buy RXO for implied value of $5.8 billion
CHRW•
Invivyd grants options for 157,500 shares to six new hires under 2026 inducement plan
IVVD•
BrilliA buys majority stake in Malaysian lingerie retailer Neubodi
BRIA•